Utility of human cytochrome P450 inhibition data in the assessment of drug-induced liver injury

References

• Brink A, Pahler A, Funk C, Schuler F, Schadt S. 2017. Minimizing the risk of chemically reactive metabolite formation of new drug candidates: implications for preclinical drug design. Drug Discov Today. 22(5):751-756.
   Google Scholar
• Chalasani N, Bjornsson E. 2010. Risk factors for idiosyncratic drug-induced liver injury. Gastroenterology. 138(7):2246-2259.
   Google Scholar
• Chen M, Suzuki A, Thakkar S, Yu K, Hu C, Tong W. 2016. DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug Discov Today. 21(4):648-653.
   Google Scholar
• Clinton JW, Kiparizoska S, Aggarwal S, Woo S, Davis W, Lewis JH. 2021. Drug-Induced Liver Injury: Highlights and Controversies in the Recent Literature. Drug Saf. 44(11):1125-1149.
   Google Scholar
• Cook D, Brown D, Alexander R, March R, Morgan P, Satterthwaite G, Pangalos MN. 2014. Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework. Nat Rev Drug Discov. 13(6):419-431.
   Google Scholar
• Dragovic S, Vermeulen NP, Gerets HH, Hewitt PG, Ingelman-Sundberg M, Park BK, Juhila S, Snoeys J, Weaver RJ. 2016. Evidence-based selection of training compounds for use in the mechanism-based integrated prediction of drug-induced liver injury in man. Arch Toxicol. 90(12):2979-3003.
   Google Scholar
• Feng S, He X. 2013. Mechanism-based inhibition of CYP450: an indicator of drug-induced hepatotoxicity. Curr Drug Metab. 14(9):921-945.
   Google Scholar
• Food and Drug Administration. 2020. In Vitro Drug Interaction Studies -Cytochrome P450 Enzyme- and Transporter-Mediated Drug Interactions Guidance for Industry.
   Google Scholar
• Frank R, Hargreaves R. 2003. Clinical biomarkers in drug discovery and development. Nat Rev Drug Discov. 2(7):566-580.
   Google Scholar
• Funk C, Roth A. 2017. Current limitations and future opportunities for prediction of DILI from in vitro. Arch Toxicol. 91(1):131-142.
   Google Scholar
• Garcia-Cortes M, Robles-Diaz M, Stephens C, Ortega-Alonso A, Lucena MI, Andrade RJ. 2020. Drug induced liver injury: an update. Arch Toxicol. 94(10):3381-3407.
   Google Scholar
• Gomez-Lechon MJ, Tolosa L, Donato MT. 2016. Metabolic activation and drug-induced liver injury: in vitro approaches for the safety risk assessment of new drugs. J Appl Toxicol. 36(6):752-768.
   Google Scholar
• Guengerich FP. 2015. Human Cytochrome P450 Enzymes. In: Ortiz de Montellano PR, editor. Cytochrome P450: Structure, Mechanism, and Biochemistry. Cham: Springer International Publishing; p. 523-785.
   Google Scholar
• Han L, Wang Y, Bryant SH. 2008. Developing and validating predictive decision tree models from mining chemical structural fingerprints and high-throughput screening data in PubChem. BMC Bioinformatics. 9:401. eng.
   Google Scholar
• Hewitt NJ, Hewitt P. 2004. Phase I and II enzyme characterization of two sources of HepG2 cell lines. Xenobiotica. 34(3):243-256.
   Google Scholar
• Kralj T, Brouwer KLR, Creek DJ. 2021. Analytical and Omics-Based Advances in the Study of Drug-Induced Liver Injury. Toxicol Sci. 183(1):1-13.
   Google Scholar
• Kuijper IA, Yang H, Van De Water B, Beltman JB. 2017. Unraveling cellular pathways contributing to drug-induced liver injury by dynamical modeling. Expert Opin Drug Metab Toxicol. 13(1):5-17.
   Google Scholar
• Lammert C, Bjornsson E, Niklasson A, Chalasani N. 2010. Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events. Hepatology. 51(2):615-620.
   Google Scholar
• Lin J, Li M, Mak W, Shi Y, Zhu X, Tang Z, He Q, Xiang X. 2022. Applications of In Silico Models to Predict Drug-Induced Liver Injury. Toxics. 10(12).
   Google Scholar
• Minerali E, Foil DH, Zorn KM, Lane TR, Ekins S. 2020. Comparing Machine Learning Algorithms for Predicting Drug-Induced Liver Injury (DILI). Mol Pharm. 17(7):2628-2637.
   Google Scholar
• Mulliner D, Schmidt F, Stolte M, Spirkl HP, Czich A, Amberg A. 2016. Computational Models for Human and Animal Hepatotoxicity with a Global Application Scope. Chem Res Toxicol. 29(5):757-767.
   Google Scholar
• Ozawa S, Miura T, Terashima J, Habano W, Ishida S. 2021. Recent Progress in Prediction Systems for Drug-induced Liver Injury Using In vitro Cell Culture. Drug Metab Lett. 14(1):25-40.
   Google Scholar
• Parkinson A, Ogilvie BW, Buckley DB, Kazmi F, Parkinson O. 2019. Biotransformation of Xenobiotics. In: Klaassen CD, editor. Casarett & Doull’s Toxicology: The Basic Science of Poisons, 9th edition. New York, NY: McGraw-Hill Education.
   Google Scholar
• Real M, Barnhill MS, Higley C, Rosenberg J, Lewis JH. 2019. Drug-Induced Liver Injury: Highlights of the Recent Literature. Drug Saf. 42(3):365-387.
   Google Scholar
• Shimizu Y, Sasaki T, Takeshita JI, Watanabe M, Shizu R, Hosaka T, Yoshinari K. 2021. Identification of average molecular weight (AMW) as a useful chemical descriptor to discriminate liver injury-inducing drugs. PLoS One. 16(6):e0253855.
   Google Scholar
• Shimizu Y, Sasaki T, Yonekawa E, Yamazaki H, Ogura R, Watanabe M, Hosaka T, Shizu R, Takeshita J, Yoshinari K. 2021. Association of CYP1A1 and CYP1B1 inhibition in in vitro assays with drug-induced liver injury. J Toxicol Sci. 46(4):167-176.
   Google Scholar
• Tolosa L, Gomez-Lechon MJ, Donato MT. 2015. High-content screening technology for studying drug-induced hepatotoxicity in cell models. Arch Toxicol. 89(7):1007-1022.
   Google Scholar
• Villanueva-Paz M, Moran L, Lopez-Alcantara N, Freixo C, Andrade RJ, Lucena MI, Cubero FJ. 2021. Oxidative Stress in Drug-Induced Liver Injury (DILI): From Mechanisms to Biomarkers for Use in Clinical Practice. Antioxidants (Basel). 10(3).
   Google Scholar
• Vo AH, Van Vleet TR, Gupta RR, Liguori MJ, Rao MS. 2020. An Overview of Machine Learning and Big Data for Drug Toxicity Evaluation. Chem Res Toxicol. 33(1):20-37.
   Google Scholar
• Walker PA, Ryder S, Lavado A, Dilworth C, Riley RJ. 2020. The evolution of strategies to minimise the risk of human drug-induced liver injury (DILI) in drug discovery and development. Arch Toxicol. 94(8):2559-2585.
   Google Scholar
• Wang MWH, Goodman JM, Allen TEH. 2021. Machine Learning in Predictive Toxicology: Recent Applications and Future Directions for Classification Models. Chem Res Toxicol. 34(2):217-239.
   Google Scholar
• Watanabe M, Sasaki T, Takeshita JI, Kushida M, Shimizu Y, Oki H, Kitsunai Y, Nakayama H, Saruhashi H, Ogura R et al. 2020. Application of cytochrome P450 reactivity on the characterization of chemical compounds and its association with repeated-dose toxicity. Toxicol Appl Pharmacol. 388:114854.
   Google Scholar
• Wilke RA, Lin DW, Roden DM, Watkins PB, Flockhart D, Zineh I, Giacomini KM, Krauss RM. 2007. Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. Nat Rev Drug Discov. 6(11):904-916.
   Google Scholar
• Wilkening S, Stahl F, Bader A. 2003. Comparison of primary human hepatocytes and hepatoma cell line Hepg2 with regard to their biotransformation properties. Drug Metab Dispos. 31(8):1035-1042.
   Google Scholar
• Wu X, Kumar V, Ross Quinlan J, Ghosh J, Yang Q, Motoda H, McLachlan GJ, Ng A, Liu B, Yu PS et al. 2008. Top 10 algorithms in data mining. Knowledge and Information Systems. 14(1):1-37.
   Google Scholar
• Yoda T, Tochitani T, Usui T, Kouchi M, Inada H, Hosaka T, Kanno Y, Miyawaki I, Yoshinari K. 2022. Involvement of the CYP1A1 inhibition-mediated activation of aryl hydrocarbon receptor in drug-induced hepatotoxicity. J Toxicol Sci. 47(9):359-373.
   Google Scholar
• Yu K, Geng X, Chen M, Zhang J, Wang B, Ilic K, Tong W. 2014. High daily dose and being a substrate of cytochrome P450 enzymes are two important predictors of drug-induced liver injury. Drug Metab Dispos. 42(4):744-750.
   Google Scholar